• Sun Pharma responded to BSE/NSE queries denying a speculative news article about a $12 billion Organon deal.
• The company clarified no material event requiring disclosure under SEBI Regulation 30 has occurred.
• Sun Pharma affirmed its commitment to high governance standards and timely material event disclosures.